ArticleMikrochimica acta2026
A dual-mode aptasensor based on UiO-66-NH₂@MOF-919 for subtype-specific detection of carbapenem-resistant Klebsiella pneumoniae.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Rapid and reliable detection of multidrug-resistant bacteria is essential for effective clinical management. In this study, we have developed a dual-mode aptasensing platform based on a core-shell MOF-on-MOF structure (UiO-66-NH₂@MOF-919) for the subtype-specific detection of carbapenem-resistant Klebsiella pneumoniae strains carrying NDM-1 and KPC-2. This bifunctional system integrates the peroxidase-like activity of the MOF-919 shell with the fluorescence quenching capability of the UiO-66-NH₂ core, enabling both colorimetric and fluorometric detection within a single platform. Benefiting from this design, the method achieves sensitive and selective detection over a wide linear range from 10 to 10⁸ CFU mL⁻¹, with low detection limits of 7 CFU mL⁻¹ for NDM-1 KP and 4 CFU mL⁻¹ for KPC-2 KP. The proposed platform exhibits good selectivity against non-target bacteria and strong anti-interference capability. Spiked recovery experiments in human serum, urine, and bronchoalveolar lavage fluid yielded recoveries ranging from 93.0% to 110.0% with RSDs below 5.0%, demonstrating good analytical accuracy and applicability in complex biological samples. Compared to conventional aptasensing systems, this approach enables dual-subtype detection within a single platform, improving analytical efficiency and practicality. This work provides a feasible strategy for MOF-on-MOF-based biosensing systems and shows promising potential for rapid clinical detection of drug-resistant bacteria.
Indexed as
Identifiers
42399479What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.